JTCS Concomitant Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

J Thorac Cardiovasc Surg 2003;126:122-123
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Discussion

The first 20% of the full text of this article appears below.

Dr T. Rosengart (Evanston, Ill). I congratulate the authors on a beautiful presentation. They certainly are pioneers in the field, together with Dick Weisel and Philippe Menasche, and really have led a growing body of evidence suggesting some very exciting work in the possibility of cell transplant.

I have four questions for Dr. Saito. The first question involves the use of 5-azacytidine to drive differentiation. Your histology very elegantly shows apparent differentiation of cell lines based upon the localization either to scar or periscar, appearing to go to a myocyte differentiation or a fibroblast differentiation. Based upon these findings, do you think that additional 5-azacytidine would be efficacious or a more prolonged predifferentiation prior to transplant?

In contrast, there certainly are a number of studies now suggesting that undifferentiated cells, bone marrow or otherwise, may equally be efficacious in driving myocardial remodeling. Given concerns potentially by the US Food and Drug Administration or other regulatory agencies in going to clinical trials in terms of mutations, potential mutations, and complications using 5-azacytidine, how do you see the role of using this or other differentiating factors?

Dr Saito. We have not seen it.

Dr Rosengart. Do you think that the azacytidine plays an important role, or do you think . . . [Full Text of this Article]


Related Article

Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction
Takayuki Saito, Jin-Qiang Kuang, Charles C. H. Lin, and Ray C.-J. Chiu
J. Thorac. Cardiovasc. Surg. 2003 126: 114-122. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.